A Lower Serum Gamma-Glutamyltransferase Level Does Not Predict a Sustained Virological Response in Patients with Chronic Hepatitis C Genotype 1

Fatih Güzelbulut*, Mesut Sezikli†, Züleyha Akkan Çetinkaya‡, Selvinaz Özkara§, Can Gönen§, and Ayşe Oya Kürdaş Övünç§

*Department of Gastroenterology, Elazığ Education and Research Hospital, Elazığ, †Department of Gastroenterology, Kocaeli Derince Education and Research Hospital, Kocaeli, Departments of ‡Pathology and §Gastroenterology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey

Background/Aims: Low gamma-glutamyltransferase (GGT) level was shown to be an independent predictor of a sustained virological response (SVR) in chronic hepatitis C. We aimed to determine factors associated with high GGT level, and to evaluate whether low GGT level is an independent predictor of a SVR in chronic hepatitis C genotype 1. Methods: We retrospectively reviewed our data of patients with chronic hepatitis C genotype 1 treated with pegylated interferon-α and ribavirin. Baseline features were compared between patients with normal and high GGT levels. Factors associated with high GGT level and those associated with a SVR were determined by univariate and multivariate analysis. Results: This study included 57 patients. Mean age was 52.28±9.35 years. GGT levels was elevated in 27 patients (47.4%). GGT levels were normal in 63.3% of the patients who achieved a SVR and in 40.7% of those who did not achieve a SVR (p>0.05). By multivariate logistic regression analysis, the presence of cirrhosis (odds ratio [OR], 9.41; 95% confidence interval [CI], 1.08 to 102.61) and female gender (OR, 6.77; 95% CI, 1.23 to 37.20) were significantly associated with high GGT level, and only rapid virological response was associated with a SVR (OR, 8.369; 95% CI, 1.82 to 38.48). Conclusions: Low GGT level does not predict a SVR; however, it may be a predictor of high fibrosis scores. (Gut Liver 2013;7:74-81)

Key Words: Chronic hepatitis C; Gamma-glutamyltransferase

INTRODUCTION

Chronic hepatitis C virus (HCV) infection is the most common cause of cirrhosis and hepatocellular carcinoma (HCC), and cirrhosis from chronic HCV infection is also the major indication for liver transplantation.1,2 Current guidelines recommended 48 weeks of treatment with pegylated interferon-α (PegIFN-α) and ribavirin combination for chronic HCV genotype 1 infection.1-3 A sustained virological response (SVR) can be attained in 40% to 60% of patients with this regimen.4-8 The likelihood of achieving a SVR can be predicted by both pretreatment and on-treatment variables. Genotype and baseline serum HCV RNA level are the most important pretreatment predictors of a SVR. A SVR is more likely in patients with HCV genotype 2 and 3 and in those with low serum HCV RNA levels.5-7,9-11 Other pretreatment predictors of a SVR are the absence of bridging fibrosis or cirrhosis on liver biopsy, the absence of hepatosteatosis, high serum alanine aminotransferase (ALT) levels, lower body weight, the absence of insulin resistance, and younger age.6-13 The most important on-treatment predictor of a SVR is the rapidity of decline in serum HCV RNA levels. A rapid virological response (RVR) is the most important predictor of a SVR independent of genotype, whereas failure to achieve an early virological response (EVR) is the most important predictor of not achieving a SVR.5,8,11-16 Low pegylated IFN-α and ribavirin dosages because of nonadherence or intolerance adversely affects SVR.8,16,17 Serum gamma-glutamyltransferase (GGT) levels have shown to be elevated in 32% to 63% of patients with chronic HCV infection.11,18-20 In some studies, low baseline GGT level was shown to be an independent predictor of a SVR.8,11,13,15,17 However, these studies did not fully evaluate other confounding factors, such as the presence of hepatosteatosis,19,21 bile duct injury,19,21
the degree of liver fibrosis, \textsuperscript{11,30} alcohol abuse, \textsuperscript{18,24} and gender, \textsuperscript{17} which might affect both GGT levels and SVR rates.

In this study, we aimed to determine factors which affect serum GGT levels, and to evaluate whether low baseline serum GGT level is an independent predictor of a SVR in patients infected with HCV genotype 1.

\textbf{MATERIALS AND METHODS}

We retrospectively reviewed our computerized data of chronic hepatitis C patients who were treated with PegIFN \( \alpha-2a \) 180 \( \mu \)g/wk and weight based ribavirin (<75 kg, 1,000 mg/day; \geq 75 kg, 1,200 mg/day) combination or PegIFN \( \alpha-2b \) 1.5 \( \mu \)g/kg/wk and weight based ribavirin (<65 kg, 800 mg/day; 65 to 85 kg, 1,000 mg/day; 85 to 105 kg, 1,200 mg/day; \geq 105 kg, 1,400 mg/day) combination from 2005 to 2009 in Gastroenterology Clinic. Of the 137 patients, 57 with the following criteria were included in this study: 1) anti-HCV and HCV RNA positivity within 6 months prior to therapy, 2) available quantitative serum HCV RNA levels at the beginning, at weeks 12, 24, and 48 of therapy, and 24 weeks after completion of therapy, 3) presence of moderate-to-severe necroinflammatory activity or significant fibrosis (Metavir F2-4) on liver biopsy, 4) absence of HCC, 5) abstinence from alcohol abuse for more than 6 months, and 6) adherence to therapy (defined as at least 80\% of the scheduled therapy dosage and duration).

Eighty patients were excluded from the study. Of these patients, 18 patients did not have available data of genotype, quantitative serum HCV RNA levels prior to or during therapy, 11 patients had non-genotype 1 infection, seven patients did not have liver biopsy specimens, and 19 had chronic kidney failure. Fourteen patients were excluded because therapy had been discontinued early due to adverse effects or complications. Also, 11 nonadherent patients were excluded.

Baseline serum aspartate aminotransferase (AST), ALT, alkaline phosphatase (ALP), and GGT values were recorded. These biochemical values were considered as an index according to the upper limit of normal (ULN). HCV RNA levels were measured using reverse transcription-polymerase chain reaction. Baseline serum HCV RNA level <800,000 IU/mL was classified as low level viremia and that \( \geq 800,000 \) IU/mL as high level viremia. Genotype was determined using a reverse hybridization assay.

RVR was defined as undetectable serum HCV RNA at week 4 of therapy. Complete EVR (cEVR) was defined as undetectable serum HCV RNA at week 12 of therapy and partial EVR (pEVR) as detectable serum HCV RNA but at least 2 log decline from baseline at week 12 of therapy. End of treatment response was defined as undetectable serum HCV RNA at the end of therapy. SVR was defined as undetectable serum HCV RNA 24 weeks following completion of therapy. Because serum HCV RNA levels were not measured in all patients at week 4 of therapy, all patients who were negative for serum HCV RNA at week 12 of therapy were defined as cEVR regardless of serum HCV RNA levels at week 4 of therapy.

Body mass index (BMI) was calculated according to the following formula: \( \text{BMI (kg/m}^2\text{)} = \text{weight (kg)/height (m)}^2\).

All liver biopsy specimens were analyzed by a single experienced pathologist. The degree of necroinflammatory activity (grade) and fibrosis (stage) were scored according to the Metavir system. No fibrosis was defined as F0, mild fibrosis as F1, moderate fibrosis as F2, severe fibrosis as F3, cirrhosis as F4, and no inflammation as A0, mild inflammation as A1, moderate inflammation as A2, severe inflammation as A3. Significant fibrosis was defined as F2-4. Liver biopsy specimens were also analyzed for the presence of hepatosteatosis and bile duct injury.

\textbf{Statistical analysis}

Baseline demographic, biochemical, and histopathologic features were compared between patients with normal serum GGT index (\( \leq 1\times \text{ULN} \)) and those with high GGT index (\( >1\times \text{ULN} \)). Factors associated with high serum GGT levels were determined by univariate and multivariate analysis. Baseline demographic, biochemical, and histological features were compared between patients who achieved an SVR and those who did not achieve an SVR, and predictors of SVR were defined by univariate and multivariate analysis.

Student’s t-test and Mann Whitney U test were performed when comparing the quantitative variables between the groups. Chi-squared test and Fisher’s exact chi-squared test were performed when comparing the qualitative variables between the groups. Logistic regression analysis was performed in multivariate analysis. A \( p<0.05 \) was considered as statistically significant. Statistical analysis were made using NCSS (NCSS Statistical Software, Kaysville, UT, USA) 2007 and PASS (NCSS Statistical Software) 2008 Statistical Software.

This study was carried out according to the Declaration of Helsinki 2004, and the study protocol was approved by the ethics committee of the institution. Written informed consent was obtained from patients.

\textbf{RESULTS}

\textbf{1. Baseline characteristics}

Fifty-seven patients with chronic genotype 1 HCV infection who were treated with PegIFN and ribavirin combination for 48 weeks were included in this study. All patients were white and 47.4\% of whom were male (\( n=27 \)) with a mean age of 52.28±9.35 years. Information on the BMI was available for 49 patients. The mean BMI was 29.4±4.5 kg/m\(^2\). None of the patients had a history of alcohol abuse within 6 months prior to therapy.

The mean serum AST (\( \times \text{ULN} \)), ALT (\( \times \text{ULN} \)), ALP (\( \times \text{ULN} \)},
and GGT (×ULN) levels were 1.69±1.08 (range, 0.65 to 6.88), 1.59±0.80 (range, 0.40 to 4.13), 0.62±0.23 (range, 0.27 to 1.41), and 1.32±1.07 (range, 0.21 to 5.80), respectively. Serum GGT levels were >1×ULN in 27 (47.4%) of the patients. The mean serum HCV RNA level was 5,697,425±10,091,987 IU/mL (range, 62,994 to 61,490,000) and 44 (77.2%) had serum HCV RNA levels ≥800,000 IU/mL.

Thirty-two (56.1%) patients had significant fibrosis (F2-4), 11 (19.3%) had cirrhosis (F4) and 21 (36.8%) had moderate-to-severe necroinflammatory activity scores (A2-3) on liver biopsy. The liver biopsy showed hepatosteatosis in 26 (45.6%) patients and bile duct injury in 32 (56.1%) patients.

Baseline characteristics of patients are shown in Table 1.

### Table 1. Baseline Patient Characteristics

| Characteristic | Value |
|----------------|-------|
| **Demographic features** | |
| Age | 52.28±9.35 (27–72) |
| Age ≥50 | 38 (66.7) |
| Male gender | 27 (47.4) |
| BMI, kg/m² | 29.4±4.5 (17.3–37.6) |
| BMI ≥30 | 22 (44.9) |
| Weight, kg | 75.30±12.44 (41–107) |
| **Laboratory** | |
| AST (×ULN) | 1.69±1.08 (0.65–6.88) |
| ALT (×ULN) | 1.59±0.80 (0.40–4.13) |
| ALP (×ULN) | 0.62±0.23 (0.27–1.41) |
| GGT (×ULN) | 1.32±1.07 (0.21–5.80) |
| HCV RNA, IU/mL | 5,697,425±10,091,987 (62,994–61,490,000) |
| **Liver biopsy** | |
| Stage | 1.82±1.39 (0–40) |
| Significant fibrosis (F2-4) | 32 (56.1) |
| Cirrhosis (F4) | 11 (19.3) |
| Grade | 1.54±0.82 (0–3) |
| Grade (A2-3) | 21 (36.8) |
| Hepatosteatosis | 26 (45.6) |
| Bile duct injury | 32 (56.1) |

Data are presented as mean±SD (range) or number (%).

2. **Univariate analysis of variables associated with high serum GGT levels**

Baseline factors that could be associated with high serum GGT levels were compared between patients with normal and high serum GGT levels (Table 2). Patients with high serum GGT levels tended to be female and obese.

The presence of moderate-to-severe necroinflammatory activity scores, significant fibrosis, cirrhosis, hepatosteatosis, and bile duct injury were more frequently seen in patients with high serum GGT levels than those with normal serum GGT levels. Serum AST, ALT, and ALP levels were also higher in patients with high serum GGT levels. Serum HCV RNA levels were similar in patients with normal and high serum GGT levels.

Serum GGT levels were significantly correlated with serum AST, ALT, and ALP levels (Table 3).

3. **Multivariate analysis of variables associated with high serum GGT levels**

Baseline demographic and histopathological factors that were significantly associated with high serum GGT levels by univariate analysis were then analyzed by multivariate analysis. Gender, BMI (≥30 kg/m²), presence of cirrhosis (F4), moderate-to-severe necroinflammatory activity, hepatosteatosis, and bile duct injury were evaluated by logistic regression analysis. After logistic regression analysis, presence of cirrhosis (odds ratio [OR], 9.41; 95% confidence interval [CI], 1.08 to 102.61) and female gender (OR, 6.77; 95% CI, 1.23 to 37.20) were significantly associated with high serum GGT levels independent of other factors (Table 4).

4. **Univariate analysis of variables associated with a SVR**

Baseline factors that could be associated with a SVR were compared between patients with and without SVR (Table 5). Patients with and without a SVR were similar in age, gender, and BMI. Low or high pretreatment viral load, serum AST, and ALP levels were also similar in patients with and without a SVR. Serum GGT levels were higher in patients without a SVR than those without a SVR, although the difference did not reach statistical significance (p=0.088).

The presence of moderate-to-severe necroinflammatory activity scores, cirrhosis, hepatosteatosis, and bile duct injury were similar in patients with and without a SVR. The presence of significant fibrosis was more likely in patients without a SVR than those with a SVR.

The proportion of patients with either a RVR or cEVR were significantly higher in patients with a SVR than those without a SVR. A SVR was achieved in 77.8% of patients with a RVR and in 63.8% of those with cEVR, whereas none of the patients with pEVR achieved a SVR.
Multivariate analysis of variables associated with a SVR

Baseline and treatment factors that were significantly associated with a SVR by univariate analysis were then analyzed by multivariate analysis. Age, serum HCV RNA levels, serum ALT levels, serum GGT levels, presence of significant fibrosis (F2-4) and RVR were evaluated by logistic regression analysis. After logistic regression analysis, only RVR was associated with a SVR (OR, 8.369; 95% CI, 1.82 to 38.48) (Table 6).

Table 2. Comparison of Variables between Patients with Normal and High Serum GGT Levels

| Variable                  | Normal GGT (n=30) | High GGT (n=27) | OR  (95% CI) | p-value |
|---------------------------|-------------------|-----------------|--------------|---------|
| Age (≥50)                 | 19 (63.3)         | 19 (59.3)       | 1.375        | 0.574   |
| <50                       | 11 (36.7)         | 8 (24.2)        | (0.453–4.175)|         |
| Gender Male               | 20 (66.7)         | 7 (26)          | (1.81–18.0)  |         |
| Female                    | 10 (33.3)         | 20 (66.7)       | 5.714        | 0.002*  |
| BMI (≥30)                 | 8 (26.7)          | 14 (46.2)       | 3.500        | 0.035†  |
| <30                       | 18 (66.7)         | 9 (33.3)        | (1.074–11.402)|        |
| HCV RNA ≥800,000          | 23 (52.3)         | 21 (57.4)       | 1.065        | 0.920   |
| <800,000                  | 7 (21.9)          | 6 (22.2)        | (0.308–3.683)|         |
| Grade 2–3                 | 6 (28.6)          | 15 (71.4)       | 5.000        | 0.005*  |
| 0–1                       | 24 (66.7)         | 12 (31.3)       | (1.547–16.162)|        |
| Significant fibrosis      | 11 (34.4)         | 21 (65.6)       | 6.045        | 0.002*  |
| Absent                    | 19 (65.6)         | 6 (24)          | (1.872–19.256)|        |
| Cirrhosis                 | 2 (18.9)          | 9 (81.1)        | 7.000        | 0.011†  |
| Absent                    | 28 (60.9)         | 18 (39.1)       | (1.354–36.180)|        |
| Hepatosteatosis           | 9 (34.6)          | 17 (65.4)       | 3.967        | 0.013†  |
| Absent                    | 21 (67.2)         | 10 (32.3)       | (1.314–11.970)|        |
| Bile duct injury          | 13 (40.1)         | 19 (59.9)       | 3.106        | 0.040†  |
| Absent                    | 17 (68)           | 8 (32)          | (1.037–9.304)|         |
| AST (≥ULN)                | 10 (33.3)         | 21 (67.7)       | 7.000        | 0.001*  |
| <1.3                      | 20 (66.7)         | 6 (23.1)        | (2.145–22.848)|        |
| ALT (≥ULN)                | 14 (41.2)         | 20 (58.8)       | 3.265        | 0.035†  |
| <1.3                      | 16 (69.6)         | 7 (30.4)        | (1.065–10.012)|        |
| ALP (≥ULN)                | 0                 | 5 (100)         | 0.423        | 0.014†  |
| <1                        | 30 (57.7)         | 22 (42.3)       | (0.308–0.581)|         |

Data are presented as number (%). Chi-square test.
GGT, gamma-glutamyltransferase; OR, odds ratio; CI, confidence interval; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; AST, aspartate aminotransferase; ULN, upper limit of normal; ALT, alanine aminotransferase; ALP, alkaline phosphatase.
*p<0.01; †p<0.05.

Table 3. Correlation between Serum GGT Levels and Serum AST, ALT, and ALP Levels

| Variable | GGT | p-value     |
|----------|-----|-------------|
| AST      | 0.647 | 0.001†      |
| ALT      | 0.431 | 0.001†      |
| ALP      | 0.600 | 0.001†      |

GGT, gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.
*Pearson correlation coefficient; †p<0.01.

Table 4. Multivariate Analysis of Factors Associated with a High Serum GGT Level

| Variable                  | p-value | OR  (95% CI) Lower | Upper     |
|---------------------------|---------|--------------------|-----------|
| Female gender             | 0.028   | 6.77               | 1.23      |
| BMI (≥30)                 | 0.072   | 5.71               | 0.85      |
| Cirrhosis (F4)            | 0.046   | 9.41               | 1.08      |
| Hepatosteatosis           | 0.177   | 3.16               | 0.59      |
| Bile duct injury          | 0.156   | 4.10               | 0.58      |
| Grade (A2–3)              | 0.301   | 2.57               | 0.43      |

GGT, gamma-glutamyltransferase; OR, odds ratio; CI, confidence interval; BMI, body mass index.
DISCUSSION

In previous studies, serum GGT levels were shown to be elevated in 32% to 63% of patients with chronic hepatitis C.\textsuperscript{11,18-20} In our study, serum GGT levels were elevated in 47% of the patients.

In the present study, we evaluated factors that could be associated with high serum GGT levels in patients with chronic hepatitis C. In univariate analysis, female gender, obesity (BMI $\geq 30$ kg/m$^2$), presence of high necroinflammatory activity and fibrosis scores, hepatosteatosis and bile duct injury, and high serum AST and ALT levels were associated with high serum GGT levels. Of these factors, female gender and presence of cirrhosis were associated with high serum GGT levels in multivariate analysis.

Some of our findings were consistent with previous studies. In the present study, the only histological factor associated with high serum GGT level was the presence of cirrhosis. However, we did not find an association between high serum GGT levels and the presence of either significant fibrosis or high necroinflammatory activity. Forns et al.\textsuperscript{20} showed that serum GGT level

Table 5. Comparison of Variables between Patients with and without a SVR

| Variable                  | SVR (n=30) | Non-SVR (n=37) | OR (95% CI) | p-value |
|---------------------------|------------|----------------|-------------|---------|
| Pretreatment              |            |                |             |         |
| Age                       |            |                |             |         |
| <50                       | 12 (63.2)  | 7 (36.8)       | 1.905       | 0.260   |
| >50                       | 18 (47.4)  | 20 (52.6)      | (0.616–5.890) | 0.716   |
| Gender                    |            |                |             |         |
| Female                    | 17 (54.8)  | 14 (45.2)      | 0.824       | 0.716   |
| Male                      | 13 (50)    | 13 (50)        | (0.290–2.340) | 0.445   |
| BMI (n=56)                |            |                |             |         |
| >30                       | 13 (59.1)  | 9 (40.9)       | 1.556       | 0.445   |
| <30                       | 13 (48.1)  | 14 (51.9)      | (0.499–4.848) | 0.088   |
| HCV RNA                   |            |                |             |         |
| <800,000                  | 9 (69.2)   | 4 (30.8)       | 2.646       | 0.172   |
| $\geq$800,000             | 21 (47.7)  | 23 (52.3)      | (0.660–9.200) | 0.325   |
| AST (xULN)                |            |                |             |         |
| <1.3                      | 15 (60)    | 10 (40.0)      | 1.700       | 0.325   |
| $\geq$1.3                 | 15 (46.9)  | 17 (53.1)      | (0.580–4.900) | 0.035*  |
| ALT (xULN)                |            |                |             |         |
| <1.3                      | 16 (69.6)  | 7 (30.4)       | 3.265       | 0.035*  |
| $\geq$1.3                 | 14 (41.2)  | 20 (58.8)      | (1.065–10.10) | 0.126   |
| ALP (xULN)                |            |                |             |         |
| <1                        | 29 (55.8)  | 23 (44.2)      | 5.043       | 0.126   |
| $\geq$1                   | 1 (20.0)   | 4 (80.0)       | (0.530–48.260) | 0.284   |
| GGT (xULN)                |            |                |             |         |
| $\leq$1                   | 19 (63.3)  | 11 (40.7)      | 2.512       | 0.088   |
| $>1$                      | 11 (36.7)  | 16 (59.3)      | (0.863–7.310) | 0.126   |
| Grade                     |            |                |             |         |
| 2–3                       | 13 (61.9)  | 8 (38.1)       | 1.816       | 0.284   |
| 0–1                       | 17 (47.2)  | 19 (52.8)      | (0.606–5.441) | 0.325   |
| Significant fibrosis      |            |                |             |         |
| Present                   | 17 (68)    | 8 (32)         | 3.106       | 0.040*  |
| Absent                    | 13 (40.6)  | 19 (59.4)      | (1.037–9.304) |         |
| Cirrhosis                 |            |                |             |         |
| Present                   | 26 (56.5)  | 20 (43.5)      | 2.275       | 0.229   |
| Absent                    | 4 (36.4)   | 7 (63.6)       | (0.584–8.862) | 0.520   |
| Hepatosteatosis           |            |                |             |         |
| Present                   | 13 (48.1)  | 14 (51.9)      | 0.710       | 0.520   |
| Absent                    | 17 (56.7)  | 13 (43.3)      | (0.250–2.018) |         |
| Bile duct injury          |            |                |             |         |
| Present                   | 15 (46.9)  | 17 (53.1)      | 1.700       | 0.325   |
| Absent                    | 15 (60)    | 10 (40)        | (0.589–4.904) |         |
| Treatment                 |            |                |             |         |
| RVR                       |            |                |             |         |
| Present                   | 14 (77.8)  | 4 (22.2)       | 7.350       | 0.002*  |
| Absent                    | 10 (32.3)  | 21 (67.7)      | (1.920–28.135) | 0.001*  |
| Complete EVR              |            |                |             |         |
| Present                   | 30 (63.8)  | 17 (36.2)      | –           |         |
| Absent                    | 0 (100)    | 0 (100)        |             |         |

Data are presented as number (%). Chi-square test and/or Fisher’s exact test.

SVR, sustained virological response; OR, odds ratio; CI, confidence interval; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; AST, aspartate aminotransferase; ULN, upper limit of normal; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; RVR, rapid virological response; EVR, early virological response.

*p<0.05; †p<0.01.
was one of the independent predictors of significant fibroinflammation and proposed a noninvasive fibroinflammation test including serum GGT level. Subsequently, Thabut et al.\textsuperscript{25} found similar results. However, these studies did not evaluate the association between serum GGT levels and the presence of cirrhosis and necroinflammatory activity.\textsuperscript{26} In study of Parise et al.,\textsuperscript{26} serum GGT level $\geq 1.5\times$ULN and $\geq 2\times$ULN were independent predictors of significant fibrosis and cirrhosis, respectively. Silva et al.\textsuperscript{27} also showed that high serum GGT level was associated with high necroinflammatory activity and high fibrosis scores. When we take into account these findings, association between high serum GGT levels and the presence of cirrhosis in our study is not surprising. The correlation between serum GGT and serum AST levels also supports this finding, because these enzymes are known to be elevated as the degree of fibrosis progresses.\textsuperscript{27-29}

The presence of bile duct injury has been shown in chronic hepatitis C patients.\textsuperscript{11,18,19,23} In study of Hwang et al.,\textsuperscript{23} bile duct injury was demonstrated in $71\%$ of patients with chronic hepatitis C and it was shown that genotype 1b, high portal inflammation score and high portal lymphoid aggregate/follicle were independent predictors of bile duct injury. However, serum GGT levels were not different between patients with and without bile duct injury.\textsuperscript{23} Similarly, Silva et al.\textsuperscript{19} did not find an association between serum GGT level and bile duct injury. On the other hand, Giannini et al.\textsuperscript{18} showed that serum GGT levels were more frequently elevated in patients with bile duct injury and that high serum GGT level was the only biochemical predictor of bile duct injury in patients with chronic hepatitis C. Although bile duct injury was present in half of the patients, there was not an association with serum GGT level and bile duct injury.

Hepatosteatosis is also frequent in chronic hepatitis C. Hepatosteatosis was present in $47\%$ of our patients. Silva et al.\textsuperscript{19} showed that hepatosteatosis was present in $73\%$ of patients with chronic hepatitis C, but there was not an association between serum GGT levels and hepatosteatosis, similar to our study. However, it should be kept in mind that the present study included only those patients with genotype 1 HCV infection, as the prevalence of hepatosteatosis differs between genotypes.\textsuperscript{30,31}

The other interesting findings of our study are that female gender was an independent predictor of high serum GGT levels and that there was not an association between age and serum GGT levels, since it is known that serum GGT levels are higher in men and increase with age.\textsuperscript{22} Although it did not reach statistical significance, serum GGT levels were higher in patients with higher BMI.

The second aim of the present study was to evaluate whether low serum GGT level was an independent predictor of a SVR. In univariate analysis, low serum ALT level, absence of significant fibrosis (F2–4), RVR, and cEVR were associated with achieving a SVR. However, logistic regression analysis revealed that only RVR was an independent predictor of a SVR. A SVR was 2.1 times more likely in patients with normal serum GGT levels than those with high serum GGT levels, but this was not statistically significant.

Since it has been shown that RVR was one of the most important predictors of a SVR,\textsuperscript{9-11,13-15} this result of the present study was not interesting.

On the other hand, the finding that normal serum GGT level was not an independent predictor of a SVR was not consistent with previous studies. High rates of response to therapy were shown in patients with chronic hepatitis C with low serum GGT levels by Mazzella et al.\textsuperscript{22} in 1994 and by Mihm et al.\textsuperscript{24} in 1996. Subsequently, many studies have revealed that normal or lower serum GGT level was an independent predictor of a SVR in chronic hepatitis C.\textsuperscript{9-11,13,17} On the other hand, Grasso et al.\textsuperscript{12} did not find an association between serum GGT level and SVR similar to our study. However, it should be kept in mind that some previous studies did not take into account the degree of necroinflammatory activity, presence of bile duct injury and hepatosteatosis.\textsuperscript{10,11,15} Akuta et al.\textsuperscript{17} did not consider the degree of necroinflammatory activity and presence of bile duct injury and Berg et al.\textsuperscript{9} did not consider the presence of bile duct injury and hepatosteatosis, when considering low serum GGT level as an independent predictor of SVR. In contrast to previous studies, we evaluated all these factors when considering whether low serum GGT level was an independent predictor of a SVR. The limitation of the present study might be that we did not take into account some factors such as insulin resistance, uric acid and cholesterol levels which might affect both SVR rates and serum GGT level.

In conclusion, presence of cirrhosis and female gender were independent predictors of high serum GGT level. In contrast to previous studies that found normal or low serum GGT level as an independent predictor of a SVR, we did not find an association between serum GGT level and SVR in the whole cohort. This might be due to our study design in which we evaluated more histological factors that might lead to both high serum GGT levels and lower SVR rates. Even though normal serum GGT level was an independent predictor of a SVR in female

| Variables | p-value | OR | 95% CI Lower | 95% CI Upper |
|-----------|---------|----|--------------|--------------|
| Age (<50) | 0.166   | 2.781 | 0.65 | 11.83 |
| HCV RNA (<800,000) | 0.210 | 2.746 | 0.56 | 13.32 |
| ALT (<1.3) | 0.142 | 2.943 | 0.69 | 12.44 |
| GGT (≥1) | 0.334 | 2.113 | 0.46 | 9.64 |
| Fibrosis (0–1) | 0.910 | 0.914 | 0.19 | 4.33 |
| RVR | 0.006 | 8.369 | 1.82 | 38.48 |

SVR, sustained virological response; OR, odds ratio; CI, confidence interval; HCV, hepatitis C virus; RNA, ribonucleic acid; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; RVR, rapid virological response.
patients in the present study, it should be kept in mind that the number of patients was limited to make a certain consideration.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264.
3. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16:75-90.
4. Escudero A, Rodriguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol 2008;23:861-866.
5. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22:832-836.
6. Sporea I, Sirli R, Curescu M, et al. Outcome of antiviral treatment in patients with chronic hepatitis C 1 HCV hepatitis. A retrospective study in 507 patients. J Gastrointestin Liver Dis 2010;19:261-264.
7. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138:116-122.
8. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008;48:1753-1760.
9. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
10. Cuenca F, Fernández C, Devesa MJ, et al. Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1. Rev Esp Enferm Dig 2010;102:234-238.
11. Villela-Noguiera CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005;39:728-730.
12. Grasso A, Maliiati F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009;51:984-990.
13. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-651.
14. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-115.
15. Bergmann JF, Vrolijk JM, van der Schaar P, et al. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007;27:1217-1225.
16. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-433.
17. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007;46:403-410.
18. Giannini E, Botta F, Fasoli A, et al. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Dig Dis Sci 2001;46:524-529.
19. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004;19:314-318.
20. Forns X, Ampuritanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36(4 Pt 1):986-992.
21. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
22. AlQaraawi AM, Sanai FM, Al-Husseini H, et al. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C. Dig Dis Sci 2011;56:1222-1228.
23. Hwang SJ, Luo JC, Chu CW, et al. Clinical, virological, and pathological significance of hepatic bile duct injuries in Chinese patients with chronic hepatitis C. J Gastroenterol 2001;36:392-398.
24. Plebani JG, Tirado CF, Pettinati HM, Kampman KM, Volpicelli JR, Oslin DW. Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addict Behav
25. Thabut D, Simon M, Myers RP, et al. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003;37:1220-1221.
26. Parise ER, Oliveira AC, Figueiredo-Mendes C, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006;26:1095-1099.
27. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
28. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-1325.
29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection, comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-36.
30. Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 2005;98:1-6.
31. Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006;12:7075-7080.
32. Friedman LS, Martin P, Munoz SJ. Laboratory evaluation of the patient with liver disease. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. Volume 2. 4th ed. Philadelphia: Saunders, 2003:661-708.
33. Mazzella G, Salzetta A, Casanova S, et al. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci 1994;39:866-870.
34. Mihm S, Hartmann H, Fayyazi A, Ramadori G. Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio. Dig Dis Sci 1996;41:1256-1264.